---
title: "Craig-Hallum 維持對 Neurogene（NGNE）的買入評級"
description: "根據 TipRanks 的數據，Sigdahl 是一位五星級分析師，平均回報率為 11.8%，成功率為 46.45%。Sigdahl 覆蓋消費週期性行業，專注於 Flutter Entertainment PLC、Super Group (SGHC) 和 Inspired Entertainment 等股票。Neurogene 的分析師共識為強烈買入，目標價格共識為 53.67 美元，比當前水平有"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/260470358.md"
published_at: "2025-10-09T13:15:43.000Z"
---

# Craig-Hallum 維持對 Neurogene（NGNE）的買入評級

> 根據 TipRanks 的數據，Sigdahl 是一位五星級分析師，平均回報率為 11.8%，成功率為 46.45%。Sigdahl 覆蓋消費週期性行業，專注於 Flutter Entertainment PLC、Super Group (SGHC) 和 Inspired Entertainment 等股票。Neurogene 的分析師共識為強烈買入，目標價格共識為 53.67 美元，比當前水平有 107.78% 的上漲空間。在今天發佈的一份報告中，H.C. Wainwright 也重申了對該股票的買入評級，目標價格為 45.00 美元

根據 TipRanks 的數據，Sigdahl 是一位五星級分析師，平均回報率為 11.8%，成功率為 46.45%。Sigdahl 覆蓋消費週期性行業，專注於 Flutter Entertainment PLC、Super Group (SGHC) 和 Inspired Entertainment 等股票。

Neurogene 的分析師共識為強烈買入，目標價格共識為 53.67 美元，比當前水平有 107.78% 的上漲空間。在今天發佈的一份報告中，H.C. Wainwright 也重申了對該股票的買入評級，目標價格為 45.00 美元。

### Related Stocks

- [NGNE.US - Neurogene](https://longbridge.com/zh-HK/quote/NGNE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Neurogene Maps NGN-401 Pivotal Rett Timeline, Mid-2026 Data Update at Guggenheim Summit | Neurogene (NASDAQ: NGNE) is advancing its genetic medicines pipeline, focusing on Rett syndrome with its lead program NG | [Link](https://longbridge.com/zh-HK/news/275981671.md) |
| BofA Reaffirms Glencore at Buy Amid Rumored Kazzinc Stake Sale | BofA Reaffirms Glencore at Buy Amid Rumored Kazzinc Stake Sale | [Link](https://longbridge.com/zh-HK/news/275470915.md) |
| 2 red-hot growth stocks to buy in 2026 | These stocks have roared higher but still have room to run. | [Link](https://longbridge.com/zh-HK/news/275694569.md) |
| Differentiated NMRA-511 Efficacy and Safety in Alzheimer’s Agitation Support Buy Rating on Neumora | Needham analyst Ami Fadia has maintained a Buy rating on Neumora Therapeutics, Inc. with a price target of $8.00, citing | [Link](https://longbridge.com/zh-HK/news/275644413.md) |
| Xylem: Strong Measurement & Control Momentum and Conservative 2026 Outlook Underpin Buy Rating | William Blair analyst Brian Drab has maintained a Buy rating on Xylem (XYL) stock, citing strong performance in Q4 with  | [Link](https://longbridge.com/zh-HK/news/275644998.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。